{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:56:45Z","timestamp":1792789005159,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>A substantial proportion of patients with giant cell arteritis (GCA) relapse despite standard therapy with glucocorticoids, methotrexate and tocilizumab. The Janus kinase\/signal transducer and activator of transcription (JAK\/STAT) signalling pathway is involved in the pathogenesis of GCA and JAK inhibitors (JAKi) could be a therapeutic alternative. We evaluated the effectiveness of JAKi in relapsing GCA patients in a real-world setting and reviewed available literature.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Retrospective analysis of GCA patients treated with JAKi for relapsing disease at thirteen centers in Spain and one center in United States (01\/2017-12\/2022). Outcomes assessed included clinical remission, complete remission and safety. Clinical remission was defined as the absence of GCA signs and symptoms regardless of the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) values. Complete remission was defined as the absence of GCA signs and symptoms along with normal ESR and CRP values. A systematic literature search for other JAKi-treated GCA cases was conducted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty-five patients (86% females, mean age 72.3) with relapsing GCA received JAKi therapy (baricitinib, <jats:italic>n<\/jats:italic>\u2009=\u200915; tofacitinib, <jats:italic>n<\/jats:italic>\u2009=\u200910; upadacitinib, <jats:italic>n<\/jats:italic>\u2009=\u200910). Before JAKi therapy, 22 (63%) patients had received conventional synthetic immunosuppressants (e.g., methotrexate), and 30 (86%) biologics (e.g., tocilizumab). After a median (IQR) follow-up of 11 (6-15.5) months, 20 (57%) patients achieved and maintained clinical remission, 16 (46%) patients achieved and maintained complete remission, and 15 (43%) patients discontinued the initial JAKi due to relapse (<jats:italic>n<\/jats:italic>\u2009=\u200911 [31%]) or serious adverse events (<jats:italic>n<\/jats:italic>\u2009=\u20094 [11%]). A literature search identified another 36 JAKi-treated GCA cases with clinical improvement reported for the majority of them.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This real-world analysis and literature review suggest that JAKi could be effective in GCA, including in patients failing established glucocorticoid-sparing therapies such as tocilizumab and methotrexate. A phase III randomized controlled trial of upadacitinib is currently ongoing (ClinicalTrials.gov ID NCT03725202).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-024-03314-9","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T07:01:52Z","timestamp":1717570912000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature"],"prefix":"10.1186","volume":"26","author":[{"given":"Javier","family":"Loricera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toluwalase","family":"Tofade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Prieto-Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Romero-Yuste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"de Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Riveros-Frutos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"Ferraz-Amaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eztizen","family":"Labrador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Maiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Becerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Narv\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gal\u00edndez-Agirregoikoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael","family":"Gonz\u00e1lez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Urruticoechea-Arana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Ramos-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"L\u00f3pez-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santos","family":"Casta\u00f1eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8935-7473","authenticated-orcid":false,"given":"Sebastian","family":"Unizony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2344-2285","authenticated-orcid":false,"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"key":"3314_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0140-6736(08)61077-6","volume":"372","author":"C Salvarani","year":"2008","unstructured":"Salvarani C, Cantini F, Hunder GG. Polymyalgia Rheumatica and giant-cell arteritis. Lancet. 2008;372:234\u201345.","journal-title":"Lancet"},{"key":"3314_CR2","first-page":"372","volume":"34","author":"J Loricera","year":"2015","unstructured":"Loricera J, Blanco R, Hern\u00e1ndez JL, et al. Use of positron emission tomography (PET) for the diagnosis of large-vessel vasculitis. Rev Esp Med Nucl Imagen Mol. 2015;34:372\u20137.","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"3314_CR3","doi-asserted-by":"publisher","first-page":"152166","DOI":"10.1016\/j.semarthrit.2023.152166","volume":"59","author":"J Narv\u00e1ez","year":"2023","unstructured":"Narv\u00e1ez J, Estrada P, Llop D, et al. Efficacy and safety of leflunomide in the management of large vessel vasculitis: a systematic review and metaanalysis of cohort studies. Semin Arthritis Rheum. 2023;59:152166.","journal-title":"Semin Arthritis Rheum"},{"key":"3314_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.intimp.2015.03.020","volume":"27","author":"J Loricera","year":"2015","unstructured":"Loricera J, Blanco R, Hern\u00e1ndez JL, et al. Biologic therapy in ANCA-negative vasculitis. Int Immunopharmacol. 2015;27:213\u20139.","journal-title":"Int Immunopharmacol"},{"key":"3314_CR5","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","volume":"387","author":"PM Villiger","year":"2016","unstructured":"Villiger PM, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomized, double-blind, placebo-controlled trial. Lancet. 2016;387:1921\u20137.","journal-title":"Lancet"},{"key":"3314_CR6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377:317\u201328.","journal-title":"N Engl J Med"},{"key":"3314_CR7","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1136\/annrheumdis-2021-220347","volume":"80","author":"SH Unizony","year":"2021","unstructured":"Unizony SH, Bao M, Han J, Luder Y, Pavlov A, Stone JH. Treatment failure in giant cell arteritis. Ann Rheum Dis. 2021;80:1467\u201374.","journal-title":"Ann Rheum Dis"},{"key":"3314_CR8","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S2665-9913(21)00038-2","volume":"3","author":"JH Stone","year":"2021","unstructured":"Stone JH, Aringer M, Blockmans D, et al. Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. Lancet Rheumatol. 2021;3:e328\u201336.","journal-title":"Lancet Rheumatol"},{"key":"3314_CR9","doi-asserted-by":"publisher","first-page":"e002923","DOI":"10.1136\/rmdopen-2022-002923","volume":"9","author":"MA Matza","year":"2023","unstructured":"Matza MA, Dagincourt N, Mohan SV, et al. Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis. RMD Open. 2023;9:e002923.","journal-title":"RMD Open"},{"key":"3314_CR10","first-page":"341","volume":"5","author":"MJ Samec","year":"2023","unstructured":"Samec MJ, Rakholiya J, Langenfeld H, et al. Relapse risk and safety of long-term tocilizumab use among patients with giant cell arteritis: a single-enterprise cohort study. J Rheumatol. 2023;5:341\u201350.","journal-title":"J Rheumatol"},{"key":"3314_CR11","doi-asserted-by":"publisher","first-page":"E341","DOI":"10.1016\/S2665-9913(23)00101-7","volume":"5","author":"N Venhoff","year":"2023","unstructured":"Venhoff N, Schmidt WA, Bergner R, et al. Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomized, double-blind, placebo-controlled, phase 2 trial. Lancet Rheumatol. 2023;5:E341\u201350.","journal-title":"Lancet Rheumatol"},{"key":"3314_CR12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1136\/annrheumdis-2021-221865","volume":"81","author":"MC Cid","year":"2022","unstructured":"Cid MC, Unizony SH, Blockmans D, et al. Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81:653\u201361.","journal-title":"Ann Rheum Dis"},{"key":"3314_CR13","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/art.40044","volume":"69","author":"CA Langford","year":"2017","unstructured":"Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol. 2017;69:837\u201345.","journal-title":"Arthritis Rheumatol"},{"key":"3314_CR14","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1161\/CIRCULATIONAHA.117.030423","volume":"137","author":"H Zhang","year":"2018","unstructured":"Zhang H, Watanabe R, Berry GJ, Tian L, Goronzy JJ, Weyand CM. Inhibition of JAK-STAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitis. Circulation. 2018;137:1934\u201348.","journal-title":"Circulation"},{"key":"3314_CR15","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1136\/annrheumdis-2021-221961","volume":"81","author":"MJ Koster","year":"2022","unstructured":"Koster MJ, Crowson CS, Giblon RE, et al. Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study. Ann Rheum Dis. 2022;81:861\u201367.","journal-title":"Ann Rheum Dis"},{"key":"3314_CR16","doi-asserted-by":"publisher","first-page":"1187584","DOI":"10.3389\/fimmu.2023.1187584","volume":"14","author":"P Eriksson","year":"2023","unstructured":"Eriksson P, Skoglund O, Hemgren C, Sj\u00f6wall C. Clinical experience and safety of Janus kinase inhibitors in giant cell arteritis: a retrospective case series from Sweden. Front Immunol. 2023;14:1187584.","journal-title":"Front Immunol"},{"key":"3314_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/RLU.0000000000003913","volume":"47","author":"K Prigent","year":"2022","unstructured":"Prigent K, Aouba A, Aide N, de Boysson H. JAK inhibitor effectiveness in giant-cell arteritis with large-vessel involvement assessed by 18F-FDG PET-CT. Clin Nucl Med. 2022;47:234\u201335.","journal-title":"Clin Nucl Med"},{"key":"3314_CR18","first-page":"71","volume":"185","author":"N Herlihy","year":"2019","unstructured":"Herlihy N, Curto-Garc\u00eda N, O\u00b4Sullivan J, et al. Successful treatment of chronic neutrophilic leukaemia and associated giant cell arteritis with the combination of ruxolitinib and azacytidine [abstract]. Br J Haematol. 2019;185:71\u20132.","journal-title":"Br J Haematol"},{"key":"3314_CR19","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1136\/annrheumdis-2021-eular.3435","volume":"80","author":"D Camellino","year":"2021","unstructured":"Camellino D, Dejaco C, Giusti A, et al. Baricitinib in Polymyalgia Rheumatica and giant cell arteritis: report of six cases [abstract]. Ann Rheum Dis. 2021;80:1216.","journal-title":"Ann Rheum Dis"},{"key":"3314_CR20","doi-asserted-by":"publisher","first-page":"e274","DOI":"10.1093\/rheumatology\/keac203","volume":"61","author":"A Sanada","year":"2022","unstructured":"Sanada A, Abe N, Bohgaki M, Kasahara H. Therapeutic effectiveness of upadacitinib combined with glucocorticoid on remission induction and maintenance in giant cell arteritis. Rheumatology (Oxford). 2022;61:e274\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"3314_CR21","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/art.1780330810","volume":"33","author":"GG Hunder","year":"1990","unstructured":"Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33:1122\u20138.","journal-title":"Arthritis Rheum"},{"key":"3314_CR22","doi-asserted-by":"crossref","unstructured":"Dejaco C, Kerschbaumer A, Aletaha D et al. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis 2023; ard-2022-223429.","DOI":"10.1136\/annrheumdis-2023-eular.254"},{"key":"3314_CR23","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/art.41774","volume":"73","author":"M Maz","year":"2021","unstructured":"Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol. 2021;73:1349\u201365.","journal-title":"Arthritis Rheumatol"},{"key":"3314_CR24","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.semarthrit.2016.11.006","volume":"46","author":"JC Wilson","year":"2017","unstructured":"Wilson JC, Sarsour K, Collinson N, et al. Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): a nested case-control analysis. Semin Arthritis Rheum. 2017;46:819\u201327.","journal-title":"Semin Arthritis Rheum"},{"key":"3314_CR25","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1136\/annrheumdis-2016-210070","volume":"76","author":"C Miyabe","year":"2017","unstructured":"Miyabe C, Miyabe Y, Strle K, et al. An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy. Ann Rheum Dis. 2017;76:898\u2013905.","journal-title":"Ann Rheum Dis"},{"key":"3314_CR26","doi-asserted-by":"publisher","first-page":"635663","DOI":"10.3389\/fphar.2021.635663","volume":"12","author":"R Bursi","year":"2021","unstructured":"Bursi R, Cafaro G, Perricone C, et al. Contribution of Janus-Kinase\/Signal Transduction Activator of Transcription Pathway in the pathogenesis of Vasculitis: a possible treatment target in the Upcoming Future. Front Pharmacol. 2021;12:635663.","journal-title":"Front Pharmacol"},{"key":"3314_CR27","first-page":"1","volume":"15","author":"L Castelo-Soccio","year":"2023","unstructured":"Castelo-Soccio L, Kim H, Gadina M, Schwartzberg PL, Laurence A, O\u00b4Shea JJ. Protein kinases: drug targets for immunological disorders. Nat Rev Immunol. 2023;15:1\u201320.","journal-title":"Nat Rev Immunol"},{"key":"3314_CR28","doi-asserted-by":"publisher","first-page":"587089","DOI":"10.3389\/fimmu.2020.587089","volume":"11","author":"R Watanabe","year":"2020","unstructured":"Watanabe R, Berry GJ, Liang DH, Goronzy JJ, Weyand CM. Cellular signaling pathways in medium and large vessel vasculitis. Front Immunol. 2020;11:587089.","journal-title":"Front Immunol"},{"key":"3314_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","volume":"12","author":"DM Schwartz","year":"2016","unstructured":"Schwartz DM, Bonelli M, Gadina M, O\u00b4Shea JJ. Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12:25\u201336.","journal-title":"Nat Rev Rheumatol"},{"key":"3314_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/rheumatology\/kex423","volume":"57","author":"N Terrades-Garcia","year":"2018","unstructured":"Terrades-Garcia N, Cid MC. Pathogenesis of giant-cell arteritis: how targeted therapies are influencing our understanding of the mechanisms involved. Rheumatology (Oxford). 2018;57:51\u201362.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03314-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-024-03314-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03314-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T07:09:43Z","timestamp":1717571383000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-024-03314-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3314"],"URL":"https:\/\/doi.org\/10.1186\/s13075-024-03314-9","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]},"assertion":[{"value":"6 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Cantabria Clinical Research Ethics Committee (approval number 2021.414), and was conducted in accordance with the Declaration of Helsinki and the International Conference for Harmonization. All data extracted from the medical records were stored de-identified prior to the analysis. As per the Clinical Research Ethics Committee, this retrospective research did not require informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Disclosures that might be interpreted as constituting possible conflict(s) of interest for the study: Javier Loricera had consultation fees\/participation in company-sponsored speaker\u00b4s bureau from Roche, AbbVie, Gal\u00e1pagos, Novartis, UCB Pharma, MSD, Celgene, Astra Zeneca, and Gr\u00fcnenthal and received support for attending meetings and\/or travel from Janssen, AbbVie, Roche, Novartis, MSD, UCB Pharma, Celgene, Lilly, Pfizer, and Gal\u00e1pagos. Diana Prieto-Pe\u00f1a has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from UCB Pharma, Novartis, Amgen, Lilly, Sanofi, and Janssen, and received support for attending meetings and\/or travel from Lilly, Roche, Sanofi, Pfizer and Abbvie. Susana Romero-Yuste has received grants\/recents supports from Abbvie, Lilly, Pfizer, and Gal\u00e1pagos. Eugenio de Miguel Research funding\/consulting and conferences fees from: Abbvie, Novartis, Pfizer, Roche, Janssen, Lilly, MSD, BMS, UCB, Gr\u00fcnenthal, and Sanofi, and received support for attending meetings and\/or travel from Abbvie, Pfizer, Sanofi, and Gr\u00fcnenthal. Iv\u00e1n Ferraz-Amaro would like to acknowledge that he has received grants\/research supports from Abbvie, MSD, Janssen, and Roche, as well as consultation fees from company sponsored speakers bureaus associated with Abbvie, Pfizer, Roche, Sanofi, Celgene, and MSD, and received support for attending meetings and\/or travel from Abbvie, MSD, Janssen, Pfizer, Roche, Sanofi, and Celgene. Eva Gal\u00edndez-Agirregoikoa had consultation fees\/participation in company-sponsored speaker\u00b4s bureau from Lilly, Janssen, Abbvie, and Amgen, and received support for attenting meetings and\/or travel from Lilly, Abbvie, and Pfizer.  Ismael Gonz\u00e1lez-Fern\u00e1ndez had consultation fees\/participation in company-sponsored speaker\u00b4s bureau from Novartis, Janssen, Grunenthal, MSD, and Theramex, and received support for attending meetings and\/or travel from Janssen, and MSD. Ana Urruticoechea-Arana had received research grants, fees for consultancies or presentations and participated in medical meetings or courses from Abbvie, Gal\u00e1pagos, UCB, Pfizer, MSD, Novartis, GSK, Hanssen, and Amgen, and participated on a data safety monitoring board or advisory board GSK. \u00c1ngel Ramos-Calvo had consultation fees\/participation in company-sponsored speaker\u00b4s bureau from Amgen, UCB, and Gal\u00e1pagos, and received support for attending meetings and\/or travel from Pfizer. Fernando L\u00f3pez-Guti\u00e9rrez received support for attending meetings and\/or travel from Janssen, Abbvie, Roche, Novartis, MSD, UCB Pharma, Celgene, Lilly, Pfizer, and Gal\u00e1pagos. Santos Casta\u00f1eda has received research supports from MSD, and Pfizer and had consultation fees\/participation in company-sponsored speaker\u2019s bureau from BMS, Eli-Lilly, MSD, Roche, and UCB, and received support for attending meetings and\/or travel from BMS, Lilly, MSD, Roche, and UCB. Sebastian Unizony received research support from Genentech, participated in an advisory board for Abbvie, and provided consulting for Sanofi, Kiniksa, and Janssen.Ricardo Blanco received grants\/research support from AbbVie, MSD, and Roche, and had consultation fees\/participation in a company-sponsored speaker\u2019s bureau from AbbVie, Pfizer, Roche, GSK, Lilly, UCB, Bristol-Myers, Novartis, Janssen, UCB and MSD, and received support for attending meetings and\/or travel from AbbVie, Pfizer, Roche, GSK, Lilly, UCB, Bristol-Myers, Novartis, Janssen, UCB, and MSD. <i>The following authors did not declare financial disclosure<\/i>: Toluwalase Tofade, Anne Riveros-Frutos, Eztizen Labrador, Olga Maiz, Elena Becerra, Javier Narv\u00e1ez. The following authors did not declare financial disclosure: Toluwalase Tofade, Anne Riveros-Frutos, Eztizen Labrador, Olga Maiz, Elena Becerra, Javier Narv\u00e1ez.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}